Sign in

GDTC on Nasdaq

CytoMed Therapeutics Ltd

CytoMed Therapeutics Ltd is a pharmaceutical preparations company, listed on Nasdaq (GDTC).1

Price unavailable

Last updated Oct 21, 2026.

Overview

$252.3KRevenue, fiscal 20252
-$3.1MNet income, fiscal 20252

Compare with Savara Inc, CytoDyn Inc. or Geron Corporation, or pick any stock.

  • TickerGDTC on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersU01
  • Incorporated inSingapore3
  • Business address#08-22 One Commonwealth, 1 Commonwealth Lane, U0 1495443
  • Filer categoryNon-accelerated filer, Emerging growth company3

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-1232.0%Net margin2
395.9%Revenue growth, 20252
-58.3%Return on equity2
0.05×Debt to equity2
-$3.4MFree cash flow2

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Business segments

CBU service & related therapy [member] brought in 50% of the revenue CytoMed Therapeutics Ltd broke down this way in fiscal 2025.

  1. CBU service & related therapy [member]324.4K SGD250%up 367% from 2024
  2. Reportable segments [member]324.4K SGD250%up 367% from 2024
Business segments by year
Business segments20242025
CBU service & related therapy [member]69.5K SGD324.4K SGD
Reportable segments [member]69.5K SGD324.4K SGD

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development99¢$1.7M
  • Interest1¢$16.3K

Out of $252.3K in revenue.2 The company lost money this year.

Financial statements

Revenue42$252.3K in 2025+396% since 2024
0$100.0K$200.0K$300.0K2024: $50.9K$50.9K20242025: $252.3K$252.3K2025+396%
Net income5642-$3.1M in 2025+33% since 2022
-$4.0M-$3.0M-$2.0M-$1.0M02022: -$2.3M-$2.3M20222023: -$3.1M-$3.1M2023+34%2024: -$1.8M-$1.8M2024−41%2025: -$3.1M-$3.1M2025+68%

Every line of the income statement as filed: the last 3 fiscal years, latest first.2

Period ending2025-12-312024-12-312023-12-31
Revenue324.4K SGD69.5K SGD
Other operating income679.7K SGD784.1K SGD803.9K SGD
Other (losses)/gains including fair value changes on financial instruments - net140.3K SGD297.5K SGD-492.9K SGD
Lab consumables and cord-blood banking expenses-68.0K SGD-17.1K SGD
Research expenses-2.2M SGD-1.9M SGD-1.6M SGD
Depreciation of property, plant and equipment-196.9K SGD-109.8K SGD-101.9K SGD
Amortization of intangible assets-29.9K SGD-12.6K SGD-2.2K SGD
Employee benefits expenses-930.6K SGD-619.3K SGD-454.1K SGD
Finance expenses-20.9K SGD-20.3K SGD-51.3K SGD
Other expenses-1.7M SGD-998.1K SGD-2.2M SGD
Share of results of associate-6.4K SGD13.8K SGD-31.2K SGD
Loss before income tax-4.0M SGD-2.5M SGD-4.1M SGD
Income tax expense-653 SGD
Foreign currency translation (loss)/gain132.0K SGD163.6K SGD-89.9K SGD
Equity holders of the Company-4.0M SGD-2.5M SGD-4.1M SGD
Non-controlling interests-15.9K SGD-5.2K SGD-274 SGD
Total-4.0M SGD-2.5M SGD-4.1M SGD
Equity holders of the Company-3.8M SGD-2.4M SGD-4.2M SGD
Non-controlling interests-15.9K SGD-5.2K SGD-274 SGD
Total-3.9M SGD-2.4M SGD-4.2M SGD
Basic-0.34 SGD-0.22 SGD-0.39 SGD
Diluted-0.34 SGD-0.22 SGD-0.39 SGD
Basic11.6M shares11.5M shares10.6M shares
Diluted11.6M shares11.5M shares10.6M shares

Compare CytoMed Therapeutics Ltd with another company

Corporate structure

CytoMed Therapeutics Ltd sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of CytoMed Therapeutics Ltd

  • Chee Kong Choo Filed SCHEDULE 13D/A on CytoMed Therapeutics Ltd, latest Oct 13, 2026 (7 filings since Apr 21, 2023)
  • mDR Ltd Filed SCHEDULE 13G/A on CytoMed Therapeutics Ltd, latest Mar 24, 2025 (3 filings since Apr 24, 2023)
  • 28 Consultants Ltd Filed SCHEDULE 13G on CytoMed Therapeutics Ltd, latest Mar 4, 2025
  • Jieming Zeng Filed SC 13G on CytoMed Therapeutics Ltd, latest Feb 14, 2024 (2 filings since May 19, 2023)
  • Shu Wang Filed SC 13G on CytoMed Therapeutics Ltd, latest Feb 14, 2024
  • CytoMed Therapeutics Ltd U0

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What CytoMed Therapeutics Ltd reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$2.9M2 Dec 31, 2025$2.4M4 Dec 31, 2024+20.6%
Operating-lease assets (leased space)54.3K SGD2 Dec 31, 202534.7K SGD2 Dec 31, 2024+56.2%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$1.6M2 Dec 31, 2025$3.7M2 Dec 31, 2024−55.4%
Long-term investments18.2K SGD2 Dec 31, 2025

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill355 SGD2 Dec 31, 2025355 SGD2 Dec 31, 20240%
Intangible assets, net (excluding goodwill)$97.1K2 Dec 31, 2025$68.1K4 Dec 31, 2024+42.6%

Leadership

Who has led CytoMed Therapeutics Ltd, and when. Pick a name to see everywhere that person has worked.

Chief financial officer

  1. Yvonne Goh2026–now

Chief operating officer

  1. Wee Kiat Tan2023
2025
Board members and other officers (11)

Former names

  • CytoMed Therapeutics Pte. Ltd.Sep 28, 2021 to Nov 30, 20223

Filings

129 filings to the SEC since October 2021: 4 annual reports, 19 insider forms, 14 large holders, 92 other. The latest 20:

  1. Oct 13, 2026SCHEDULE 13D/A EDGAR
  2. Oct 13, 20266-K EDGAR
  3. Sep 30, 20266-K EDGAR
  4. Aug 11, 2026144 EDGAR
  5. Jul 24, 20264/A EDGAR
  6. Jul 24, 2026SCHEDULE 13D/A EDGAR
  7. Jul 24, 20264 EDGAR
  8. Jun 23, 20266-K EDGAR
  9. Jun 15, 20264 EDGAR
  10. Jun 3, 20266-K EDGAR
  11. May 26, 20263 EDGAR
  12. May 15, 20263 EDGAR
  13. May 15, 20263 EDGAR
  14. May 15, 20263 EDGAR
  15. May 15, 20263 EDGAR
  16. May 15, 20263 EDGAR
  17. May 15, 20266-K EDGAR
  18. May 13, 2026144 EDGAR
  19. May 11, 20266-K EDGAR
  20. Apr 14, 20266-K EDGAR

The 129 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

5 open-market trades by officers, directors and large owners since October 2021: 5 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jul 20, 2026Choo Chee KongDirectorBuy100,000$1.50$150.0KForm 4
Jul 20, 2026Choo Chee KongDirectorBuy100,000$1.50$150.0KForm 4
Jul 14, 2026Choo Chee KongDirectorBuy100,000$1.50$150.0KForm 4
Jul 14, 2026Choo Chee KongDirectorBuy100,000$1.50$150.0KForm 4
May 13, 2026Choo Chee KongDirectorBuy112,000$1.15$128.8KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How CytoMed Therapeutics Ltd is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARCytoMed Therapeutics Ltd1
  • CIK0001873093
  • Filer statusNon-accelerated filer an emerging growth company; a shell company22
  • Incorporated inSingapore22
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address#08-22 One Commonwealth, 1 Commonwealth Lane, U0 1495441
  • Phone6038249111
  • Shares outstanding11,828,435 shares as of Dec 31, 202522
  • AuditorWWC, P.C., San Mateo, California PCAOB ID 1171; no auditor attestation of internal control over financial reporting22
  • On EDGAR sinceSep 28, 20211
  • Filings130 in all: 6-K (41), 3 (16), CORRESP (9), UPLOAD (9), 144 (7), F-1/A (5), SC 13G (5), 20-F (4)1
    All 29 form types

    SCHEDULE 13D/A (4), DRS/A (3), DRSLTR (3), 4 (2), 6-K/A (2), EFFECT (2), FWP (2), SC 13D (2), SEC STAFF LETTER (2), 4/A (1), 424B4 (1), 424B5 (1), 8-A12B (1), CERT (1), DRS (1), F-1 (1), F-3 (1), S-8 (1), SC 13G/A (1), SCHEDULE 13G (1), SCHEDULE 13G/A (1)

  • Latest filingsAnnual report (20-F) Mar 31, 2026

Securities registered for trading

ClassSymbolExchange
Ordinary shares, no par value per shareGDTCNasdaq

From the cover page of the 20-F filed Mar 31, 2026 (Section 12(b) of the Exchange Act).22

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22